GLP-1 injection site placement: what the evidence actually shows

What did @drjonesdc actually say?

The creator argued that injection site location does not meaningfully change GLP-1 results at a population level, but individual variability means your personal best spot could differ significantly from someone else's. The practical takeaway was: test sites yourself, and use that experimentation to stay on the lowest effective dose.

Specifically, the claim was that "collectively across thousands of people, the absorption is almost identical, regardless of where you inject," while simultaneously arguing that individual differences can be as large as 20% between sites. They also floated the idea that plateau-breaking by switching injection sites is a real phenomenon, not just placebo.

Does the science back this up?

The population-level claim is largely supported. The individual variability claim is real but probably overstated in how it was framed. Studies do confirm that absorption differences exist, but the 20% figure is not something the creator sourced, and it deserves scrutiny.

A pharmacokinetic review by Heise et al. (2014, Diabetes, Obesity and Metabolism) examined subcutaneous injection sites for insulin and GLP-1 class drugs and found that while small differences in absorption rates exist between abdomen, thigh, and upper arm, peak plasma concentrations and overall bioavailability are not dramatically different. A study by Gradel et al. (2018, Basic and Clinical Pharmacology and Toxicology) specifically examined subcutaneous drug behavior and confirmed that local tissue blood flow and adipose tissue depth are the primary drivers of variability, which does support the individual-differences argument. However, these studies do not confirm a precise 20% figure for GLP-1 receptor agonists specifically, and that number appears to be an extrapolation or estimate rather than a cited finding.

What did they get wrong (or right)?

They got the core message right. Site equivalency at the population level is well-established, and the individual variability concept is biologically grounded. Credit where it is due: this is more nuanced than most TikTok health content.

What they got wrong, or at least sloppy, is the specific 20% figure. Dropping a precise number without a source is exactly the kind of thing that spreads as fact across patient communities. The creator says "the data also shows massive individual variability" but never names the data. "Massive" is doing a lot of work in that sentence. The actual literature suggests variability exists but describes it as modest to moderate, not massive. The plateau-breaking anecdote is also presented as if it has direct clinical evidence behind it. It does not, at least not for GLP-1 medications specifically. It is a plausible mechanism, not a proven one. The suggestion to use site-testing as a tool to stay on the lowest dose is genuinely reasonable advice, even if it is framed more confidently than the evidence warrants.

What should you actually know?

Approved GLP-1 medications like semaglutide and tirzepatide are designed for subcutaneous injection in the abdomen, thigh, or upper arm. The manufacturers' clinical trial data was collected using these three sites interchangeably, which is part of why we know population-level differences are small.

What actually matters more than site selection is injection technique: rotating within a site to avoid lipohypertrophy (scar tissue buildup), injecting into healthy subcutaneous fat rather than muscle or skin, and keeping the medication stored correctly before use. Lipohypertrophy from repeated same-spot injections can genuinely reduce absorption, and that is a clinically documented problem (Blanco et al., 2013, Diabetes Research and Clinical Practice). If you are experiencing inconsistent results, that is worth discussing with a licensed prescriber, not just experimenting with sites on your own. Individual variation is real, but self-experimentation without clinical guidance has limits.

The bottom line

This video is better than average for the category. The core claims are defensible. The framing occasionally outruns the evidence, particularly around the 20% figure and the plateau-breaking narrative. If you are on a GLP-1 medication and curious about injection site effects, the honest answer is: rotation and technique matter more than which site you pick, and your prescriber is the right person to talk to if your results feel inconsistent.